A number of hormonal approaches for prevention of endometrial and breast cancers have been proposed. Because of the hormonal responsiveness of both tumors, much attention has focused on effects of exogenous hormone use. Although estrogens in hormone replacement therapy increase the risk of endometrial cancer, the disease is substantially reduced by long-term use of oral contraceptives. The issues with breast cancer are more complex, mainly because of a variety of unresolved effects. Long-term estrogen use is associated with some increase in breast cancer risk, and certain patterns of oral contraceptives appear to predispose to early-onset disease. With respect to estrogens, preventive approaches for both tumors would include use for as limited periods of time as possible. Addition of a progestin appears to lower estrogen-associated endometrial disease, but its effect on breast cancer risk remains less clear. Additional studies on effects of detailed usage parameters should provide useful insights into etiologic mechanisms. Other preventive approaches for endometrial cancer that may work through hormonal mechanisms include staying thin, being physically active, and maintaining a vegetarian diet. Breast cancer risk may possibly be reduced by extended periods of breastfeeding, restriction of intake of alcoholic beverages, remaining thin later in life, and being physically active. Additional research is needed to clarify the biologic mechanisms of these associations. The bridging of epidemiology with the biologic sciences should clarify many unresolved issues and lead to better preventive approaches. -Environ Health Perspect 103(Suppl 8): 185-189 (1995) 
Introduction
Both endometrial cancer and breast cancer have been shown to be hormonally responsive tumors. It is not surprising therefore that these tumors are affected by both hormone replacement therapy and oral contraceptive usage. Thus, a major focus of the present paper is on defining exogenous hormonal relationships for these tumors. Although much is known about their effects, a number of unresolved issues remain. Further information on effects would be useful in terms of promoting better recommendations for usage and clarifying etiologic mechanisms. Prevention has also been approached through alterations in lifestyle factors, most of which are thought to affect risk through hormonal mechanisms. Ultimately, however, prevention will depend on better understanding the biology of the tumors. Therefore, the final section of this paper will focus on future research priorities, which should integrate epidemiology with biochemical approaches.
Hormone replacement therapy consists of either estrogen alone or estrogen combined with a progestin. In the United States, the most commonly used menopausal hormones are conjugated equine estrogens and medroxyprogesterone acetate. Their use may be either short-term or long-term. Short-term use is for the relief of symptoms at the time of the menopause and may be for a few months or years. Long-term use is intended to prevent osteoporosis and fractures and cardiovascular diseases. To achieve maximum preventive benefit, hormone use should be, essentially, life-long. However, such usage may be associated with some adverse effects, including increased risk of both endometrial and breast cancers.
Oral contraceptives are for the most part combination products of an estrogen plus a progestin. The estrogen is either ethinyl estradiol or mestranol (the latter is metabolized in the body to the former), but the progestins are more varied. They are derived from either the 17-hydroxyprogesterone compounds (norethindrone is a prototype) or the 19-nor testosterone compounds. The latter have greater androgenic activity than the former.
Since the relationship of hormones to risk of ovarian and cervical cancers has been addressed elsewhere (M Pike, personal communication), the present review will focus on cancers of the breast and endometrium. However, it is worth noting that the risk of ovarian cancer can be substantially reduced by long-term use of oral contraceptives (1) . Effects of hormones on cervical cancer remain less clear (2) because little research has been conducted on menopausal hormone relationships. More research has been conducted on the etiologic role of oral contraceptives, and some studies show that long-term use increases the risk of invasive cervical cancer. However, in the United States, where cervical cytology is commonly used, the precursor lesions are usually identified and treated well before invasive cancer develops. The possible risk of cervical cancer from oral contraceptives (or from any other cause) can essentially be eliminated with regular (every 1 to 3 years) cervical cytologic screening.
Endometrial Cancer
It has been well demonstrated that estrogens cause endometrial cancer at the doses normally consumed for either acute symptoms or long-term prevention. The effect is Environmental Health Perspectives duration dependent; i.e., longer use confers greater risk (3) (4) (5) . Ten years of use can produce an 8-to 10-fold increase in risk. In some studies, cessation of use appears to be associated with a relatively rapid decrease in risk, although other studies suggest that elevated risk may continue for some time after discontinuation (3) (4) (5) . In general, the disease produced is not an extremely aggressive cancer (6,7), but mortality, nonetheless, appears elevated (8) .
Progestins have been shown to produce regressive changes in endometrial hyperplasia, a presumed precursor of endometrial cancer (9) . This has led to widespread enthusiasm for combining estrogen therapy with progestins to combat carcinogenic effects. Although lower rates of endometrial hyperplasia have been seen among those receiving combined therapy than among women receiving estrogens alone, effects on endometrial cancer remain less clear. In one recent study (10) , the addition of a progestin for 10 or more days each month considerably reduced endometrial cancer risk. Whether or not the risk associated with estrogens may be completely obliterated by the addition of progestins remains unresolved.
The situation with oral contraceptives and endometrial cancer is quite clear. Oral contraceptives reduce the risk of endometrial cancer, with the greatest benefit occurring among long-term users, whose risk is reduced by approximately half that of nonusers (11) (12) (13) (14) . Some Although there is contradictory evidence regarding the effect of estrogens on breast cancer risk, a number of studies suggest that long-term use (10 years or more) may result in increased relative risks of the magnitude of 1.4 to 1.8 (19) (20) (21) (22) (23) (24) . Some data suggest that current use may also be adverse (24) (25) (26) , but many studies do not support such an effect. The effect of combined estrogen/progestin therapy is less certain because the experience in the United States with that regimen has not been sufficiendy long (27) . Data in this country are just now accumulating. However (40, 41) . Several studies have emphasized the importance of change in recent weight, possibly reflecting its role in adult adiposity. There is also accumulating evidence that fat distribution may predict breast cancer risk among postmenopausal women, with abdominal obesity being more hazardous than peripheral accumulation. Further, recent results support the possible importance of physical activity in preventing breast cancer (42) . Adolescent physical activity has been shown to be particularly important in reducing risk, possibly through a delay in the onset of menarche. Thus, the interrelationships of body size, diet, and physical activity obviously merit further research. Finally, recent attention has focused on avoidance of certain environmental factors (most notably, pesticide residues) (43) as a means of breast cancer prevention, although much further research is needed to clarify how risk might be affected.
Like endometrial cancer, breast cancer has been shown to be influenced by reproductive patterns. The age at first birth has been shown in many studies to be an important determinant of risk. Since this is not a readily modifiable lifestyle factor, it is encouraging that recent studies are showing some consistency regarding a protective effect of breastfeeding on breast cancer risk (44, 45) . However, some studies support that breastfeeding may only protect against premenopausal breast cancer, and it remains unclear whether the limited durations of breastfeeding of most women in the United States will be sufficient to alter breast cancer risk. Nonetheless, given the widespread potential for this intervention, it is obvious that further exploration of its preventive mechanisms regarding breast cancer should be pursued.
Future Research
To be successful in gaining new information for prevention, our research strategies must change. We should increase our efforts in molecular/biochemical epidemiology. This field combines rigorous epidemiologic study designs with the technology and innovation of molecular biology. Molecular epidemiology allows for study of cellular and molecular alterations in somatic tissue (the target tissue for cancer) and in germline tissue. In somatic tissue, there are opportunities to study markers in precursor lesions or in cancer tissue. Precursor lesions are of particular interest in etiology and pathogenesis. Markers found in precursor lesions can be related to those identified in invasive cancers as well as to hormonal interventions and other risk factors identified through more traditional epidemiologic methods.
Endogenous hormones represent a biomarker that is being increasingly examined with respect to the etiology of endometrial and breast cancers. Endometrial cancer is a particularly appropriate cancer to approach from a biochemical/epidemiologic perspective, since there is such clear evidence of the influence of ovarian hormones on risk. A unified theory of how risk factors might operate through one common hormonal pathway has been suggested ( Figure 1 For epidemiologists to join forces with laboratory scientists, a significant amount of bridging work is needed. This requires transitional epidemiologic studies that employ biochemical or molecular markers from human tissues or fluids and that bridge the gap between innovative laboratory technology and assays that can be used in population-based epidemiologic research. These studies address laboratory issues of quality control, assay accuracy and replicability within and across laboratories, feasibility, and standardization. The epidemiologic issues concern tissue collection acceptable to subjects, and specimen transport and storage consistent with the needs of the laboratory. Unless time is devoted to these types of studies, we will have many failures and waste significant amounts of scientific energy and resources.
Last, attention must be focused on translational research. The synthesis of knowledge from multiple scientific disciplines to develop and undertake a research agenda should bring us closer to solving problems than would be achieved merely by approaching issues through the vision of a singular discipline. It is also the rationale for and means by which the prevention trials of promising strategies and agents can be designed and operationalized. The potential for application of research findings to the reduction of human cancer incidence must be an important criterion for our research agenda.
